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We present a case of primary caffeine dependence based 
on the exclusive use of over-the-counter caffeine tablets. 
Caffeine has recently undergone scrutiny as a co-morbid risk 
factor with other substance dependencies, and in other medi-
cal and psychiatric conditions. Caffeine withdrawal also is 
briefly discussed with attention given to personality factors 
and the use of nicotine. Although caffeine generally is consid-
ered safe in usual doses, it is a substance potentially able to 
result in serious dependence. We cite a case which also illus-
trates that a supportive inpatient milieu may be necessary in 
order to interrupt a cycle of heavy caffeine use resulting in 
marked dependence. 
Introduction 
Despite its ubiquitous use1·2·3 and acceptance as a relative-
ly safe drug, caffeine has recently come under scrutiny as a 
potent pharmacologic agent that exerts significant effects on 
a number of organ systems. Investigators have examined the 
possible adverse role of caffeine in affecting hypertension, 
coronary artery disease, hyperlipidemia, irritable bowel syn-
drome, peptic ulcer and pancreatic cancer3•4• Psychiatric liter-
ature has reported that caffeine has exacerbated panic disor-
der5, anxiety6•3, depression6, schizophrenia' and insomnia1•3•6 • 
In addition, caffeine has received recent interest as a risk fac-
tor for relapse among patients suffering from alcohol or nico-
tine dependence8• 
Epidemiologic evidence suggests that the average intake of 
caffeine by adult Americans is approximately 200 mg to 220 
mg a day1,3, and that intake in excess of 788 mg a day proba-
bly occurs in only 0.1% of the population 1, which would cor-
respond to the intake of approximately 9 cups of brewed cof-
fee. Our report describes primary caffeine dependence in an 
otherwise healthy man and illustrates that caffeine itself, 
regardless of co-existing medical or psychiatric conditions, 
has the potential to act as a drug that can be abused with seri-
ous consequences. 
Case Report 
The patient was a married 29-year-old man who was 
referred to the Psychiatric Inpatient Service of Tripier Army 
Medical Center (TAM C) for treatment of primary caffeine 
dependence. The medical history revealed in addition a con-
sumption of 40 to 60 cigarettes a day for 11 years, but other-
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wise, the patient had no significant medical or psychiatric 
problems or history of alcohol or illicit drug abuse. The 
patient began the use of over-the-counter caffeine tablets 
approximately 10 years prior to admission. He began taking 
one or two 100 mg tablets at night to help him remain alert 
while moonlighting at a second job. The patient's primary 
job as a radio operator required protracted attention to detail 
in an often lengthy procession of incoming traffic messages, 
which then required prioritization and dissemination. Shifts 
lasting from 8 to 15 hours heightened the appeal of caffeine's 
stimulating effect. As tolerance developed, the patient 
increased his dosage pattern to 3 or more times a day for a 
total daily consumption of 1600 to 2000 mg. A typical regi-
men consisted of two 200 mg caffeine tablets 4 times a day. 
The patient's longest period of abstinence was 6 months, 
after he was moved from shore duty onto a ship where caf-
feine tablets were not available. Interestingly, he denied the 
use of caffeine-containing beverages. When asked why he 
sought help to stop his use of caffeine, he cited a chief com-
plaint of recurrent withdrawal headaches (which he medicat-
ed with 1 to 2 caffeine tablets), as well as chronic irritability 
and an increasing concern for his long-term health. 
Because he had demonstrated the inability to stop the use 
of caffeine on his own, he was admitted to Inpatient 
Psychiatry in order to provide environmental and pharmaco-
logic support in case of serious caffeine withdrawal symptoms. 
On day 1, he denied headache but complained of general-
ized anxiety and a sense of feeling trapped. On day 2, he 
complained of a dull, bifrontal headache of an intensity 5110 
associated with nasal fullness (this responded to Motrin and 
Actifed), as well as generalized fatigue. On day 3 his 
headache was significantly reduced to 1 to 2/10. His daytime 
sleep reduced from 4 hours to approximately 1 hour. On day 
4, he began to experience an increased subjective sense of 
energy and well-being and no longer asked for medication 
for headache. On day 5, he again experienced significant 
daytime somnolence requiring several naps. Day 6 was 
essentially without physical complaint, and he was dis-
charged on day 7. 
At no time did he complain of cardiac symptoms, mus-
cle tension, tremulousness, nausea or dyspepsia. Although 
irritable at times, his affect was appropriate in the milieu 
of the ward and he was a highly verbal participant in 
group sessions. 
Discussion 
Primary caffeine-dependence is rare. Pathologic con-
sumption of caffeine is most often associated with an attempt 
to manage intentional or inadvertent withdrawal from 
amphetamine or other sympathomimetic drugs. This patient's 
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consumption of caffeine in tablet form, 
coupled with his distaste for caffeine-
containing foods and beverages, rein-
forces the notion that the consumption 
is for the sole purpose of achieving an 
altered state (psychotropic effect). 
Our patient clearly met the diag-
nostic criteria for psychoactive sub-
stance-use disorder. Over time he had 
consumed caffeine in even larger 
amounts, more than he had intended, 
and his history revealed unsuccessful 
attempts to control this abuse. He had 
achieved marked tolerance. He had 
experienced an abstinence syndrome 
and he had taken caffeine to relieve 
or avoid these withdrawal symptoms. 
He had continued its use despite the 
presence of negative consequences 
and he was concerned about his long-
term health. 
The patient's withdrawal symptoms 
were uncharacteristically mild; his 
response to Motrin and Actifed was 
unexpected but gratifying. Caffeine-
withdrawal headache is classically 
reported to be of a severe, generalized, 
vascular type accompanied by photo-
phobia and nausea in 25% of suffer-
ers.2·6. Traditional treatment regimens 
are those used in cases of severe 
migraine. A partial explanation for this 
patient's relatively mild withdrawal is 
not unusual considering the wide range 
of individual differences in both toler-
ance and withdrawal from methylxan-
thines. Personality factors including 
extroversion, tendency to avoid somati-
zation, and self-assessment of overall 
good health (this patient displayed all) 
have been associated with the ability to 
tolerate and enjoy the effects of high 
doses of caffeine1.2• 
These personality traits also have 
been associated with a decreased 
intensity of withdrawal headaches. A 
significant factor could be that the 
patient smoked cigarettes, since nico-
tine has been shown to decrease signif-
icantly the plasma half-life of caffeine 
by as much as 50%6•9 • In addition, the 
patient's reported withdrawal symp-
toms during previous attempts to dis-
continue caffeine were apparently 
much worse than the withdrawal he 
reported while he was hospitalized. 
This suggests that the additional psy-
chological factors were operating 
within the inpatient milieu. Thus, 
removing the patient from his regular 
daily stressors, providing pharmaco-
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logic support of his withdrawal symp-
toms and providing an aura of safety in 
the ward may have been instrumental in 
interrupting the cycle of compulsive 
abuse in this case. 
In cases involving heavy compulsive 
caffeine use such as this, brief inpatient 
hospitalization deserves consideration. 
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